Items Tagged ‘riboiclib’

March 16, 2017

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer


The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical […]

View full entry

Tags: Breast Cancer, kisqali, Metastatic Breast Cancer, News, riboiclib, Stages II-III Breast Cancer